Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Public ClinicalTrials.gov record NCT02127970. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Study identification
- NCT ID
- NCT02127970
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Durata Therapeutics Inc., an affiliate of Allergan plc
- Industry
- Enrollment
- 698 participants
Conditions and interventions
Conditions
Interventions
- Dalbavancin Drug
- Dalbavancin-matching Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 17, 2014
- Primary completion
- Mar 10, 2015
- Completion
- Mar 10, 2015
- Last update posted
- Sep 27, 2018
2014 – 2015
United States locations
- U.S. sites
- 25
- U.S. states
- 12
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 110 | Montgomery | Alabama | 36106 | — |
| 103 | Anaheim | California | 92804 | — |
| 117 | Long Beach | California | 90806 | — |
| 106 | Long Beach | California | 90813 | — |
| 118 | Modesto | California | 95350 | — |
| 104 | San Diego | California | 92120 | — |
| 113 | San Diego | California | 92120 | — |
| 115 | San Diego | California | 92120 | — |
| 116 | San Diego | California | 92120 | — |
| 108 | Stockton | California | 95204 | — |
| 105 | Sylmar | California | 91342 | — |
| 112 | Washington D.C. | District of Columbia | 20037 | — |
| 107 | Orlando | Florida | 32806 | — |
| 120 | Saint Cloud | Florida | 34769 | — |
| 114 | Augusta | Georgia | 30909 | — |
| 122 | Columbus | Georgia | 31904 | — |
| 125 | Savannah | Georgia | 31405 | — |
| 119 | Eunice | Louisiana | 70535 | — |
| 101 | Springfield | Massachusetts | 01199 | — |
| 109 | Detroit | Michigan | 48202 | — |
| 121 | Butte | Montana | 59701 | — |
| 123 | Omaha | Nebraska | 68131 | — |
| 111 | Toledo | Ohio | 43608 | — |
| 126 | Franklin | Tennessee | 37064 | — |
| 127 | Smyrna | Tennessee | 37167 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02127970, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 27, 2018 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02127970 live on ClinicalTrials.gov.